Patent · US Active

Antisense compounds targeting genes associated with cystic fibrosis

US9840709B2 · kind B2 · utility

4Cited by
0References
26Claims
0Family size

Assignee

Inventor

Key dates

Filing dateFeb 17, 2016
Grant dateDec 12, 2017
Priority date—
Expiry dateFeb 17, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/33
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.